Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Atezolizumab
Drug ID BADD_D00179
Description Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy.[L7489] Atezolizumab was granted FDA approval on 18 October 2016.[L7489]
Indications and Usage Atezolizumab is indicated to treat locally or advanced metastatic urothelial carcinoma in patients ineligible for cicplatin-containing chemotherapy with tumors expressing PD-L1, in patients ineligible for cisplatin-containing chemotherapy irrespective of PD-L1, have disease progression following platinum containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant chemotherapy.[L7489] Atezolizumab is also indicated first line for non small cell lung cancer in combination with bevacizumab, paclitaxel, and carboplatin with no EGFR or ALK genomic abnormalities.[L7489] It can be used in patients with disease progression during or after platinum containing chemotherapy even if they have EGFR and ALK abnormalities.[L7489] Atezolizumab is indicated in combination with paclitaxel protein-bound to treat locally advanced or metastatic triple negative breast cancer expressing PD-L1.[L7489] Finally, atezolizumab is indicated in combination with carboplatin and etoposide as first line treatment for extensive stage small cell lung cancer.[L7489]
Marketing Status approved; investigational
ATC Code L01FF05
DrugBank ID DB11595
KEGG ID D10773
MeSH ID C000594389
PubChem ID Not Available
TTD Drug ID Not Available
NDC Product Code 12806-0917; 50242-918; 50242-917
UNII 52CMI0WC3Y
Synonyms atezolizumab | anti-PDL1 | immunoglobulin G1, anti-(human CD antigen CD274) (human monoclonal MDPL3280a heavy chain), disulfide with human monoclonal MDPL3280a kappa-chain, dimer | MPDL3280A | MPDL-3280A | Tecentriq | RG7446 | RG-7446
Chemical Information
Molecular Formula Not Available
CAS Registry Number 1380723-44-3
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Alanine aminotransferase increased13.03.04.005--
Anaemia01.03.02.001--
Arthralgia15.01.02.001--
Aspartate aminotransferase increased13.03.04.011--
Back pain15.03.04.005--
Blood creatinine increased13.13.01.004--
Constipation07.02.02.001--
Cough22.02.03.001--
Diarrhoea07.02.01.001--
Dyspnoea02.11.05.003; 22.02.01.004--
Fatigue08.01.01.002--
Haematuria21.10.01.018; 24.07.01.047; 20.02.01.006--
Hyperglycaemia14.06.02.002; 05.06.02.002--
Hypoalbuminaemia14.10.01.002; 09.01.02.003--
Hyponatraemia14.05.04.002--
Lymphopenia01.02.02.002--Not Available
Nausea07.01.07.001--
Neck pain15.03.04.009--
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Vomiting07.01.07.003--
Blood alkaline phosphatase increased13.04.02.004--
Decreased appetite14.03.01.005; 08.01.09.028--
The 1th Page    1    Total 1 Pages